preservation in women with RMD treated with CYC. Although CYC is used less frequently than in the past due to availability of alternative treatments, it remains a mainstay of therapy for severe or life-threatening RMD. Ovarian insufficiency is a potential long-term complication of monthly intravenous CYC therapy. Hormonal co-therapy during the course of CYC is suggested to reduce risk of ovarian insufficiency. Fertility preservation with cyclophosphamide To prevent inducing primary ovarian